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Abstract
Background: Malaria elimination requires a variety of approaches individually optimized for different transmission settings.
A recent field study in an area of low seasonal transmission in South West Cambodia demonstrated dramatic reductions in
malaria parasite prevalence following both mass drug administration (MDA) and high treatment coverage of symptomatic
patients with artemisinin-piperaquine plus primaquine. This study employed multiple combined strategies and it was
unclear what contribution each made to the reductions in malaria.
Method and Findings: A mathematical model fitted to the trial results was used to assess the effects of the various
components of these interventions, design optimal elimination strategies, and explore their interactions with artemisinin
resistance, which has recently been discovered in Western Cambodia. The modelling indicated that most of the initial
reduction of P. falciparum malaria resulted from MDA with artemisinin-piperaquine. The subsequent continued decline and
near elimination resulted mainly from high coverage with artemisinin-piperaquine treatment. Both these strategies were
more effective with the addition of primaquine. MDA with artemisinin combination therapy (ACT) increased the proportion
of artemisinin resistant infections, although much less than treatment of symptomatic cases with ACT, and this increase was
slowed by adding primaquine. Artemisinin resistance reduced the effectiveness of interventions using ACT when the
prevalence of resistance was very high. The main results were robust to assumptions about primaquine action, and
immunity.
Conclusions: The key messages of these modelling results for policy makers were: high coverage with ACT treatment can
produce a long-term reduction in malaria whereas the impact of MDA is generally only short-term; primaquine enhances
the effect of ACT in eliminating malaria and reduces the increase in proportion of artemisinin resistant infections; parasite
prevalence is a better surveillance measure for elimination programmes than numbers of symptomatic cases; combinations
of interventions are most effective and sustained efforts are crucial for successful elimination.
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Introduction
Elimination of malaria from much of the world is a declared
aim of the World Health Organization [1] and is currently being
attempted or planned in many countries [2]. As the epidemiology
of malaria varies widely, malaria elimination requires a variety of
approaches individually optimized for different transmission
settings. It is expensive and slow, or often impossible, to develop
these approaches by trial and error in the field [3]. Mathematical
modelling is a rapid, low cost means of using limited available data
to compare large numbers of strategies and optimize their impact.
It has great potential to help guide the efforts to achieve
elimination [3]. Very little mechanistic modelling of malaria
elimination has been attempted thus far [3]. One exception is
models developed for malaria elimination in the context of newly
discovered artemisinin resistance in Western Cambodia [4] for
which mathematical modelling is helping to guide planning.
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Unfortunately, there are limited data on which to base models of
malaria elimination using modern methods.
From 2004–2007, a large field study of malaria elimination
using antimalarial drugs (termed ‘FEMSE’, Fast Elimination of
Malaria by Source Eradication) in South-Western Cambodia was
undertaken. Using mass drug administration and treatment with
both artemisinin-piperaquine and primaquine the study was
successful in reducing substantially the prevalence of malaria
parasite positive individuals in most of the 26 villages studied, with
elimination in 7 [5]. As in much of the region this was an area of
low, unstable, seasonal, mostly forest fringe malaria transmission.
The study was in two small areas of Kampot and Kampong Speu
Provinces. The overall Annual Parasite Incidence (API) in 2004 in
these provinces was around 6–8 confirmed cases per 1000
population per year [6,7]. The results of this field study were in
broad agreement with findings from previous mathematical
modelling for Cambodia which showed that strategies that
included high coverage of treatment with artemisinin combination
therapies (ACT) can achieve large reductions over a similar
timescale [4]. However, the malaria elimination field trial in South
West Cambodia employed multiple strategies both simultaneously
and sequentially and it was not known to what extent each strategy
contributed to the successful outcomes. The execution of the trial
varied geographically. This variation in the strategies employed
between different sites, together with frequent monitoring of
parasite rates, provided a range of data which could be used for
fitting and validation of a mathematical model designed to answer
specific questions about the trial.
These questions included the relative impact of mass drug
administration versus augmented coverage of routine treatment
(Rx) and whether adjunctive primaquine (PQ) in a single
gametocytocidal dose was a worthwhile addition to either [8]. In
the trial, primaquine MDA was given in a dose of 9 mg every 10
days for 6 months, an intervention that would be very resource
intensive to replicate on a large scale. In two sub studies, an
additional round of MDA was tried using ACT with single dose
primaquine, one study at 42 days and another at 1 year. Large
studies in the Comoros (32,519 subjects) [9] and Cambodia
(28,143 subjects) [10] found mass administration of repeated low
dose primaquine (9 mg) to be safe and well tolerated. Elsewhere,
larger gametocytocidal doses of primaquine have been used
[11,12] and currently 0.75 mg/kg base as a single dose is
recommended by the World Health Organization [13]. In a
single dose, primaquine is currently under consideration for mass
deployment in Cambodia [14] although there remains uncertainty
over the optimum dose and benefit-risk ratio for this potentially
haemolytic drug. Similarly a two day regimen was used for the
ACT in the field trial as opposed to the more usual three days, also
recommended by WHO [13]. The optimal dosing for these drugs
is the subject of ongoing study.
There was concern, as in other areas, that reducing malaria
prevalence will reduce population level immunity and a failed
attempt at elimination might result in a subsequent rebound
increase in malaria morbidity and mortality. The studied
intervention was for three years following which malaria control
measures were relaxed. Although the study population was
screened for parasitaemia every 6 months, numbers of clinical
cases were not recorded and active surveillance was discontinued
at the end of the trial so inferences about changing population
level immunity could not be made.
It was also not known if artemisinin resistance was present in the
area during the study and what impact this may have had on the
effectiveness of these strategies, or how these strategies may have
affected the spread of drug resistance.
It is particularly urgent and important to answer these questions
as ACT-based strategies are currently under consideration for
malaria elimination throughout Cambodia [14] and in many
similar countries worldwide and there is considerable ongoing
debate about the possible impact of artemisinin resistance [4] and
the potential role of primaquine [3,8].
Detailed data from the Cambodian field study were used in
combination with a range of other studies to develop and validate
a mathematical model of P. falciparum malaria transmission for
Cambodia. This model was used to answer a number of specific
questions for the Cambodia National Malaria Control Programme
to help with their planning of malaria elimination efforts. The
broad aims were: 1. separate and quantitate the effects of the
various components of the strategies used in the field study and
predict their long-term impact; 2. explore interaction of these
strategies with artemisinin resistance; and 3. design optimal
elimination strategies. The results were distilled into five key
implications for malaria elimination policy.
Methods
A deterministic mathematical model of P. falciparum malaria
transmission was developed using the Berkeley MadonnnaTM
software package (California, USA). The model structure is shown
diagrammatically in figure 1 and as equations in Supporting
Information S1. It incorporates stages of the P. falciparum life cycle
in humans, antimalarial drug action, resistance to artemisinin and
piperaquine, antidisease immunity, asymptomatic infection [15],
births, non-disease deaths and details of the strategies employed in
the trial. The basic framework was developed from a previously
published model for artemisinin resistance [4] with major
additions and modifications including the addition of host
immunity and asymptomatic infections [15] using a method based
on that of Aguas et al [16] and formal and extensive model fitting
to, and validation with, malaria surveillance data and results from
the field study (for details, see Supporting Information S2).
Symptomatic infection was assumed to occur only in those with
asexual parasites in the peripheral blood. Artemisinin resistance
was modelled as previously using increased parasite clearance rates
derived from field studies in Pailin, Cambodia [4], which first
identified prolonged parasite clearance rates [17] although the
prevalence was varied to explore its effect on the impact of the
strategies under consideration. Parameters for malaria epidemiol-
ogy were matched to those for the field study area and the
strategies used in the trial were replicated in detail. Although
similar reductions in parasite prevalence were found for P. vivax
and P. malariae in the trial, only P. falciparum was modelled.
The modelled strategies were various combinations of:
N Treatment of symptomatic cases:
# artemisinin-piperaquine ACT
# adjunctive single dose of primaquine
N Mass drug administration:
# artemisinin-piperaquine ACT
# adjunctive single dose of primaquine
# multiple doses of primaquine: one dose given every 10 days
for 6 months
N Long-lasting insecticide treated bed nets (LLITN)
ACT was given as a 2 day course of artemsinin-piperaquine
(ArtequickH, Guangzhou, People’s Republic of China; 125 mg
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and 750 mg once a day respectively for adults) and each dose of
primaquine was 9 mg. In the figures, for brevity, an adjunctive
single dose of primaquine is referred to as ‘single primaquine’ and
multiple doses of primaquine MDA as ‘multiple primaquine’.
Model Assumptions are listed in table S1. Model parameters
and their sources are listed in table S2 with references in
Supporting Information S3.
The fitted model was used to answer the following questions:
N What was the contribution of each component of the trialled
strategies to the reductions in P.falciparum malaria burden?
N What will happen to the P. falciparum malaria burden (clinical
cases and asymptomatic parasitaemic individuals) once these
interventions are stopped at the end of the trial?
N What was the relative effect of the different strategies on
population level immunity i.e. proportions of symptomatic
versus asymptomatic cases?
N What would be the effect of artemisinin resistance on the
effectiveness of these strategies and how do they affect its
spread?
N What is the optimal design for an elimination strategy using
these methods to achieve maximum long-term impact on P.
falciparum malaria parasite prevalence?
Results
Fitting and validation of model with field data
The model was able to reproduce closely malaria surveillance
data from the national malaria control programme (figure 2A) and
the results of the study (figure 2B–E) with realistic values for
coverage with the various components of the strategies employed.
Further details of the fitting and validation are given in the
supporting information with derived coverages for the various
components of the interventions shown in table S3.
Figure 1. Summary of structure of mathematical model. A shows the basic model unit with parasite life cycle stages in the human host,
antimalarial drug action and immunity. B shows the unit in A repeated three times to track parasites resistant to artemisinins and ACT partner drug. C
shows multiple repetitions of B to reproduce the various strategies used in the trial. In A, ‘blood stage’ refers to individuals with asexual stage
parasites in the peripheral blood but no gametocytes and ‘infectious stage’ is individuals with gametocytes.
doi:10.1371/journal.pone.0037166.g001
Optimising Strategies for Malaria Elimination
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Analysis
Contribution of each component. Figure 3 shows the
modelled effect of each component of the elimination strategies
employed in the study using the coverages of 78% for treatment
and 95% for MDA derived from fitting the model to data (table
S3). Results for gametocyte carriage are shown in figure S1.
The model showed that MDA produced most of the initial
reduction in parasite prevalence. ACT MDA reduced parasite
prevalence by 26% and the addition of multiple rounds of
primaquine MDA increased this to 65% (figure 3A), whereas
adding a single dose of primaquine to ACT MDA had ,1%
additional affect. Timing of the primaquine dose simultaneously
with the ACT was partly responsible for this limited effect
observed in the model, and later doses had more effect.
Introducing ACT treatment without MDA produced an initial
drop in parasite prevalence of 23%, less than that due to MDA
alone at the same coverage. Changing treatment to ACT plus
single dose primaquine added a further 20% initial drop in
prevalence to that due to MDA. MDA alone at an estimated
coverage of 95% was insufficient to achieve elimination (defined as
,1 malaria parasitaemic individual), producing only a temporary
reduction in the number of cases lasting under 1 year following
Figure 2. Model fits to data and validation. Model predictions are shown as red lines and surveillance data in black (subgroups) or blue
(summary). A Model validated with to surveillance data for Kampot Operational District (OD) (2004–2010). The malaria control strategies used are
shown. B–E Model fitted to data from the field study (2004–2007). B–C Reductions in P. falciparum asexual stage parasite (B) and gametocyte (C)
prevalences in 17 villages in Kampong Speu OD. The strategy used was treatment with ACT plus single dose adjunctive primaquine for three years
and a single MDA with ACT and multiple rounds of primaquine MDA. D Reduction in P. falciparum asexual parasite prevalence in 3 villages in Kampot
OD with MDA and treatment as above, although with lower coverage, followed by a second MDA of ACT plus single dose adjunctive primaquine with
higher coverage (dotted line) at 42 days. E Reduction in P. falciparum asexual parasite prevalence in 4 villages in Kampong Speu OD with the same
strategy as D but with the second MDA (dotted line) at 1 year.
doi:10.1371/journal.pone.0037166.g002
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which the parasite prevalence returned to the pre-intervention
equilibrium. This was because the timing of the MDA was not
optimal (see below), coverage and adherence were not 100% and it
was not logistically feasible to provide MDA to the whole
population simultaneously. Transmission occurred from infected
people who had not yet received MDA and even with repeated
rounds of MDA, there was ongoing transmission in the time
between rounds.
The long-term decrease in prevalence was mostly due to the
introduction and continuation for 3 years of high coverage ACT
for treatment of people with fever (figure 3B). This effect was
significantly enhanced (10–13% additional decrease in parasite
prevalence) by the addition of a single dose of primaquine
treatment. In the field study the high coverages were achieved by
use of trained village malaria workers and a high profile
advertising strategy.
Sensitivity analyses found the relative effects of different
strategies to be robust to changes in coverage for the interventions,
duration of immunity and the proportion of immune patients who
became symptomatic. Changes in immunity did not alter the effect
of MDA but did change the impact of treatment. Varying the
duration of immunity from 1 day to 5 years produced a
diminishing decrease in the size of the initial drop in parasite
prevalence due to introducing high coverage with ACT treatment
from 34% to 13%. Varying the proportion of immune patients
who became symptomatic from 0–100% changed the initial drop
in prevalence resulting from this ACT treatment from 13–34%.
The predicted time to elimination (,1 parasitaemic individual)
for the main study intervention of a combination of simultaneous
introduction of high coverage with ACT plus single dose
primaquine for treatment and MDA with ACT plus multiple
doses of primaquine every 10 days for 6 months was 4.2 years. A
second round of single dose MDA made little difference to this
result. Without primaquine treatment, continued use of high
coverage ACT treatment after MDA with multiple doses of
primaquine eliminated malaria more slowly over 7.3 years. These
times are relatively long because of the high baseline parasite
prevalence in the study population and incomplete adherence to
the medication (assumed for this study to be 77%).
The predicted times to elimination were affected greatly by
parameter values used for immunity despite immunity having no
direct effect on transmissibility in the model. This was because
immunity affected the proportion of cases that became symptom-
atic and were treated. Assuming 10% of immune patients were
symptomatic, changing the duration of immunity between e.g. 1
day, 1, 2 and 3 years increased the time to elimination
exponentially from 1.2, 4.1, 9.2 and 23.2 years and longer
durations of immunity precluded elimination. If 20% of immune
patients were symptomatic, these times were reduced to 1.1, 3.3,
6.1 and 9.2 years with elimination in 21.3 years with immunity
lasting 5 years. Greater percentages of immune patients being
symptomatic further reduced the times to elimination as more of
them received treatment.
The results were robust to altering the parameters for
primaquine efficacy. The effect of low dose primaquine (9 mg)
on liver stage parasites is unknown and probably very small.
Varying the rates of clearance of liver stage parasites due to
primaquine in the model made no noticeable difference to the
relative effect of strategies including primaquine or the times to
elimination. The efficacy of this low dose of primaquine on
gametocytes is also uncertain, although known to be significant at
larger doses. Its effectiveness was thus varied from that estimated
for 0.75 mg/kg (see table S2) to an effect 4 times smaller. Large
reductions in primaquine efficacy against gametocytes were
required to significantly alter the results. When the effectiveness
of primaquine against gametocytes or the coverage of primaquine
was halved, the time to elimination for ACT plus primaquine
MDA and treatment increased from 4.2 to around 5.2 years and,
when halved again, to 7.2 years.
Cessation before elimination. The model was used to
predict what might happen when the study ended in 2007 if funds
were not available to continue to provide ACT+single dose
primaquine treatment at high coverage. To simulate this,
primaquine was stopped and coverage with ACT treatment
reduced from 78% to 19% at this time (figure 4). These coverages
were derived from fitting the model to surveillance and trial data.
The model predicted a steady increase in parasite prevalence over
the following three years to a new equilibrium level. This would be
the scenario if an elimination effort had to stop before total
elimination had been achieved because of insufficient long-term
funding or policy changes.
Population level immunity. The field study demonstrated a
fall in the prevalence of P. falciparum parasitaemia over the three
year study period but did not collect data on the numbers of
symptomatic malaria cases. Similar reductions in parasite rates
were found for P. vivax and P. malariae, although these were not
modelled. The model indicated that numbers of symptomatic
cases do not mirror numbers of people with parasites because of
changing levels of immunity which protect people from symp-
tomatic infection. Rather, falling immunity leads to an increase in
the proportion that is symptomatic. The model also predicted that
with a successful elimination strategy, as numbers of parasitaemic
Figure 3. Contribution of each component of the strategies employed on P. falciparum overall parasite prevalence. Each panel shows
the additional effects of adding primaquine to MDA with ACT. A MDA alone and B MDA combined with simultaneous introduction of ACT plus or
minus single dose adjunctive primaquine for treatment. Black line is no treatment, blue lines are no treatment (A) or treatment with ACT (B), red/pink
lines are treatment with ACT plus primaquine.
doi:10.1371/journal.pone.0037166.g003
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people continue to fall, numbers of symptomatic cases can level off
or even increase as population level immunity declines (figure 4).
Following the end of the field study, the model predicted an initial
large increase in symptomatic cases to numbers greater than
before the study period despite malaria parasite prevalence being
lower. This was because of the reduction in population level
immunity during the intervention when there were fewer
infections.
To assess the sensitivity of these results to the duration of
immunity, its mean value was varied from 0.5–5 years. The longer
lasting the immunity, the lower the number and proportion of
symptomatic cases. In addition, a longer duration of immunity
reduced the relative impact of increasing coverage with treatment
but not the other interventions. This was because it increased the
proportion of asymptomatic cases. Even with a duration of
immunity of 5 years, however, a high coverage with ACT
treatment was still the most effective strategy in the long-term. The
other results reported above were robust to this changing duration
of immunity. Increasing the percentage of immune patients who
became symptomatic delayed the increase in both symptomatic
and asymptomatic infections upon cessation of the intervention
because their numbers fell further during the intervention as a
higher proportion was treated.
Artemisinin resistance. In the model, the effectiveness of
treatment and MDA with ACT on parasite prevalence was
reduced by increasing the prevalence of artemisinin resistance
(figure 5). In these simulations, the effectiveness of ACT waned
over time as the resistant infections spread more quickly in the
presence of continuing high coverages with ACT treatment. Once
coverage with ACT treatment fell at the end of the trial, both
artemisinin sensitive and resistant infections increased and the
resistant proportion increased more slowly as the selection pressure
was reduced. Figure 5A shows the effect of artemisinin resistance
on the impact of treatment with ACT plus MDA with ACT and
multiple rounds of primaquine. The addition of Primaquine to
each treatment (figure 5B) largely negated this effect.
Compared to before the trial when malaria treatment in the
study area was thought to have comprised a variety of non-
artemisinin antimalarials and low level artemisinin monotherapy,
the proportion and number of artemisinin resistant infections
increased much more quickly when ACT was introduced for
treatment and only slightly more when MDA was added as well
(figure 5C). Single dose primaquine added to ACT treatment
greatly slowed this increase in artemisinin resistance. This was
because it reduced transmission of resistant parasites sufficiently to
prevent epidemic behaviour of the resistant subpopulation.
Multiple rounds of primaquine MDA greatly decreased the
number of resistant infections whereas a single round of
primaquine MDA did not (5D). The proportion of resistant
infections was unaffected by a single primaquine MDA but
increased slightly when multiple rounds of primaquine MDA were
added (5C). This apparent paradoxical increase was because
primaquine further reduced the number of infections and thus
population level immunity. Infections could then spread more
rapidly in the population, although only resistant infections
increased in number as selection pressure from ACT continued
to reduce the number of sensitive infections. In contrast, the effect
of adding primaquine to treatment was cumulative over the course
of the study and this ongoing additional effect was sufficient to
prevent the spread of both sensitive and resistant infections. This
was robust to varying the duration of immunity between 0.5 and 5
years.
Optimization and design of future studies
The model was used to design optimal elimination strategies for
testing in future field studies. This was done by varying timing of
the different components, combining different interventions and
investigating the effect of adding new interventions that were not
in the field study, e.g. transmission blocking by insecticide treated
bed nets.
Timing. There were no significant differences in the long-
term rates of decline or times to elimination when interventions
were introduced together at different times of year (figure 6A).
Although combined strategies which included MDA caused a
predicted greater initial decline in parasite prevalence if intro-
duced when seasonal malaria was not at peak prevalence, this
difference was not maintained. This is because the impact of the
MDA was short-lived. There was thus no clear optimal time for
simultaneous introduction of MDA plus treatment (as was done in
the trial, figure S2A). When multiple interventions were
introduced in the model at different times, however, the relative
timing of each intervention became important, as outlined below.
Combining Interventions. Combinations of interventions
were predicted by the model to be much more effective than single
interventions. This was particularly true when combining strate-
gies which act at different parts of the parasite life cycle e.g. ACT
against blood-borne parasites and transmission-blocking measures
against mosquitoes, specifically long-lasting insecticide treated bed
nets. The effect of multiple interventions using multiple different
antimalarial drugs was greatest when they were introduced at
different times (figure 6B). The optimal time for a single round of
MDA was from 6 to 12 weeks before the nadir of seasonal parasite
prevalence (figure S2B). In the field study, the MDA was
approximately 14 weeks before the nadir. Where two or three
rounds of MDA were used in the model, they had maximal impact
if the final round of MDA was completed before the nadir e.g. one
round each month for three months. When doing this, 3 rounds of
ACT MDA over 3 months was found to be optimal and of
comparable efficacy to the 19 rounds of primaquine MDA over 6
months used in the trial. MDA with multiple rounds of primaquine
was most effective after a single round of ACT MDA when started
at trough parasite prevalence. These optimal timings were because
the effects of the different strategies overlapped and with shorter
Figure 4. Population level immunity. Predicted numbers of
symptomatic cases and proportion with parasites in the blood before,
during and after the trial. The red line is the percent of the population
with blood stage parasites and the black line is the number of
symptomatic cases. The * indicates the paradoxical increase in clinical
cases despite a decrease in the proportion affected.
doi:10.1371/journal.pone.0037166.g004
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intervals the effects of the additional benefit from each strategy
were reduced.
Transmission blocking. Insecticide treated bed nets were
predicted to have a relatively large additional impact whenever
they were introduced in addition to antimalarials. The optimal
time was as early as possible, regardless of season (figure 6B). This
was despite assuming only 30% efficacy in reducing transmission
and was robust to changes in coverage from 50–100%. This large
additional effect of bed nets was true for all strategies due to their
transmission-blocking action at a different stage of the parasite life
Figure 5. Artemisinin resistance and different elimination strategies. Effect of an increasing prevalence of resistance (defined as the
proportion of infections which are artemisinin resistant) from 0% to 80% on the success of MDA with ACT plus multiple rounds of primaquine and
treatment with A ACT or B ACT plus single dose primaquine from 2004–2007. C–D effects of different treatment and MDA regimes on the spread of
artemisinin resistance (C: prevalence of resistant infections, D: number of resistant infections), presuming a starting prevalence of resistance of 5%.
Interventions ceased in 2007.
doi:10.1371/journal.pone.0037166.g005
Figure 6. Effect of varying the timing of interventions. A Varying the season in which interventions are implemented. MDA with ACT+multiple
primaquine and Rx with ACT+single primaquine started together at different times during the malaria season: when parasite prevalence is falling, at
trough, rising or at peak. B Simultaneous versus sequential interventions and the additional effect of bed nets. Simultaneous introduction of
treatment with ACT+single primaquine plus MDA with ACT+multiple primaquine (red) versus optimally timed sequential interventions (black): a.
treatment with ACT+single primaquine then b. MDA with ACT+primaquine at 9 weeks before the nadir and c. another MDA with multiple primaquine
at the nadir and the same simultaneous interventions with the addition of long lasting insecticide treated bed nets with 30% coverage (blue).
doi:10.1371/journal.pone.0037166.g006
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cycle from antimalarials. Bed nets alone, however, were never
sufficient to eliminate malaria and combination with other
interventions was always required to achieve this.
Optimal elimination strategy. From this model can be
derived an optimum strategy for malaria elimination in this
context. The most robust modelling results were that ACT
treatment with high coverage is an essential component without
which elimination cannot be achieved. If continued for long
enough at high coverage, this alone may be sufficient. Adding
adjunctive primaquine to ACT treatment accelerated elimination
and adding other interventions (MDA and LLITNs) further
accelerated the process. To achieve maximal impact, MDA should
be used as levels of infection fall in the low season and multiple
rounds of MDA should be completed before the seasonal nadir in
parasite prevalence. Three rounds of ACT MDA over three
months were found to be optimal with little advantage from
adding primaquine MDA.
Discussion
Mathematical modelling using data from a recent field trial in
Cambodia showed that the major contributor to the large
reductions in parasite prevalence seen over 3 years was use of
high coverage with artemether-piperaquine ACT for treatment of
fever cases. In contrast, MDA with this ACT produced a large
initial drop in infected people but its effect was not sustained
beyond 1 year. This was primarily because the MDA was only
employed for a short period and the number of infections
increased again after it ceased whereas artemether-piperaquine
ACT treatment continued for the entire 3 year study period.
Although the initial effect of MDA was greater than that of
treatment, the cumulative effect of longer availability of ACT
treatment was greater in the long-term.
From field studies, it is not clear to what extent 9 mg of
primaquine affects gametocytes and reduces malaria transmission.
The effect of a higher single dose of adjunctive primaquine [13]
carries a greater risk of haemolysis but its gametocytocidal effect
may be greater. To achieve the best fits of the model to field data
required the inclusion of an effect of a similar magnitude to
0.75 mg/kg. When this was included in the model, the effect of
ACT used for treatment was significantly enhanced by the
addition of a single dose of primaquine, as recently found in a
field study in Myanmar, using 0.75 mg/kg [11]. These findings
provide support for large scale deployment of primaquine to help
eliminate malaria but highlight the need for dose ranging studies.
Primaquine is now being considered for country-wide use in
Cambodia as an adjunct to ACT with the aim of elimination [18].
For primaquine MDA, the modelling results were less encour-
aging. The modelling indicated that adding a single round of
primaquine MDA had very little impact on numbers of infections,
and the cumulative effect of multiple rounds would be required.
Multiple repeated doses of primaquine given as MDA more than
doubled the initial effect of the ACT MDA in the model. This
would be impractical and costly to implement on a large scale. A
more pragmatic strategy would be to do several rounds of MDA,
one every few weeks. Three rounds of MDA with ACT were found
to be optimal in the model and most effective if completed in the 3
months before the nadir in parasite prevalence.
As well as uncertainties about the effective dose, there remains
another important barrier to the rollout of primaquine. It can
cause dangerous haemolysis in people with certain types of a
common genetic abnormality, Glucose-6-phosphate dehydroge-
nase (G6PD) deficiency. This effect is thought to be dose related
and administration of a single low dose, as was used in this trial,
should minimize this. In the modelled field study, no cases of
significant haemolysis were reported. Previous studies in Cambo-
dia and Myanmar with 9 mg and 0.75 mg/kg base respectively
did not encounter problems with haemolysis [10,11]. It is not
certain how prevalent G6PD deficiency is in Cambodia (estimates
range from 15–20%, the most common variant being G6PD
Viangchan (871G.A) [19,20]) and field studies are currently
underway to investigate this.
The model was used to predict changes in immunity and
symptomatic cases after the end of the trial. Immunity in malaria
remains poorly understood; this is an important limitation for any
model of malaria. We thus chose a relatively simple structure for
immunity that has been previously validated for a range of
transmissions settings. We also varied the parameters used for
immunity within wide ranges to check the robustness of the results.
In the model, when ongoing high coverage with ACT and single
dose primaquine treatment was stopped, mimicking cessation of
the project, a subsequent steady rise in parasite prevalence was
predicted. In addition, due to a decrease in the population level
immunity, the number of clinical cases initially increased to levels
greater than before the intervention. This was despite continued
availability of ACT at a lower rate of coverage. This would be the
situation if a short-term elimination strategy were attempted and
then funding withdrawn when numbers of infections were low.
This, combined with the long-term decrease being primarily due
to the ACT treatment illustrate the importance of ensuring
sufficient long-term funding is available for elimination pro-
grammes. Even with a successful ongoing malaria elimination
strategy, in some situations, numbers of symptomatic cases in the
model were seen to increase. This was because as numbers of
infected people fell, population immunity decreased and the
proportion of people who were symptomatic increased. In the
initial stages of an elimination strategy this can result in a levelling
off or even increase in the number of symptomatic cases, although
this will subsequently fall as numbers of infected people continue
to decline [15]. This phenomenon has been observed in the field
[21,22], although it has not been possible to separate the role of
declining immunity from other possible contributors. Regardless,
the cumulative number of clinical cases following an intervention
is always predicted by the model to be lower than if there had been
no intervention. Where this paradoxical effect occurs, an
intervention may appear falsely to be failing. Malaria surveillance
systems typically rely on numbers of reported cases in the absence
of data on asymptomatic parasitaemia (passive surveillance) and
this finding highlights the importance of regular population
screening for overall parasite prevalence to capture both the
symptomatic and asymptomatic cases [23], to get a more accurate
picture of the effectiveness or otherwise of elimination strategies.
When the intervention was stopped in the model, numbers of
symptomatic cases increased more rapidly than overall numbers of
parasitaemic people due to a lack of immunity in the population
following the period of low prevalence. In this case, although
obviously undesirable, this rapid rise may be beneficial as an early
warning sign of increasing parasite prevalence.
This modelling exercise showed that to have a realistic chance
of eliminating malaria from an area, a combination of different
strategies is required. MDA can significantly reduce the number
of infections in the short term (in this study ,1 year), particularly
when repeated in the low transmission season, but high coverage
with ACT is also required for a prolonged period (4–7 years in
this study). Elimination is greatly accelerated by the co-
deployment of long-lasting insecticide treated bed nets and
further enhanced by the transmission blocking effect of adjunctive
primaquine treatment. All this requires significant investment
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including in longer-term initiatives such as training large numbers
of village malaria workers to provide high coverage ACT in
remote areas. This is the current strategy adopted by Cambodia
which is embarking on a massive scale up of the village malaria
worker scheme with funding from the Global Fund to Fight Aids,
Tuberculosis and Malaria.
One potential spanner in the works that has not been
considered in this model is population migration. In-migration
of infected individuals reintroduces infection which can make
elimination significantly more challenging. There are little data on
migration of different population groups in many malaria endemic
countries, including Cambodia, and the degree of risk to any
future elimination programme is uncertain. Attempts are being
made in Cambodia to address this issue and studies are underway
to quantify and characterize population migration. If in-migration
of infected individuals is a significant contributor to malaria
transmission in Cambodia these migrant groups must somehow be
included in any elimination strategy, most likely using a similar
combined approach to that outlined above.
Another potential limitation of this model was the assumption
that only a single infection occurs at any one time in an individual.
Although usually true in low transmission settings [24], this is not
the case where transmission is high. It is not known how such
multiple clones would interact and affect the transmission
dynamics thus it is difficult to predict how they may impact on
the results presented (Table S1). For this to be modelled
realistically, further clinical and laboratory research is needed.
A reassuring finding from the model was that artemisinin
resistance, in its current mild form [17], does not appear to have a
large impact on the effectiveness of the regimes used in the trial for
elimination. This was true even with the current highest estimate
of 10% of infections being resistant [24]. In the presence of
hypothetical very high modelled prevalences of artemisinin
resistance (70–80%), the effect of ACT was clearly diminished
but the addition of primaquine to the ACT largely negated this
reduction. As in a previous model of artemisinin resistance [4],
ACT accelerated the increase in the number and proportion of
artemisinin resistant infections, despite greatly decreasing the
number of artemisinin sensitive infections. This was worsened by
the addition of ACT MDA. This increase in resistance was
significantly slowed by the addition of primaquine to ACT
treatment as it had sufficient antimalarial action to decrease the
overall numbers of both resistant and sensitive infections. These
findings may be different if the current mildly resistant phenotype
changes to be more resistant, although this was not included here
as it is known what form this phenotype may take.
The model was used to explore a number of scenarios that were
not included in the original field study. This was in order to
explore possible means of optimizing the strategies used in order to
assist with planning future field studies. Using modelling this way
can be much more rapid and efficient than trialling multiple
variants of strategies in the field. The modelling indicated that
multiple combined interventions are more effective than single
interventions and it is preferable to use different interventions
which impact on the same part of the parasite life-cycle
sequentially rather than simultaneously to maximize their long-
term impact. This is presumably because there is a maximum
effect for drugs with a similar mechanism of action and additional
drugs will have no additional impact beyond this maximum. The
addition of long-lasting insecticide treated bed nets to any strategy
greatly enhanced its effectiveness, despite assuming low efficacy
and coverage and a duration of action of only 2 years. There was
no advantage to delaying their introduction as they act on an
entirely different part of the parasite life cycle.
The modelling results from this study can be summarized as five
major policy implications (listed in table 1). Although this model
was developed specifically for Cambodia, these broad recommen-
dations are relevant to malaria elimination efforts worldwide.
In conclusion, mathematical modelling when validated by good
quality field data can combine information from diverse sources and
be used as a tool for enhanced analysis to provide new insights into
the results of clinical studies, to make predictions and to assist with
planning future studies. This study has provided predictions and a
number of novel insights which will be of direct practical benefit to
assist planning of future malaria elimination strategies, particularly
in the context of the newly emerging artemisinin resistance.
Supporting Information
Figure S1 Contribution of each component of the
strategies employed in the field study to the reduction
in the percent of the population with P. falciparum
gametocytes. Each panel shows the additional effect of adding
primaquine to MDA with ACT with A MDA alone, B MDA
combined with simultaneous introduction of ACT plus single PQ
for treatment. Blue lines are treatment with ACT, red lines are
treatment with ACT plus primaquine.
(TIF)
Figure S2 Effect of varying the timing of interventions
on the prevalence of parasitaemia in the population. A
MDA with ACT plus multiple primaquine and Rx with ACT plus
single primaquine started together at different times after the start
of 2004 (in months). B MDA with ACT plus multiple primaquine
at different times after introducing Rx with ACT plus single
primaquine in 2004 in months.
(TIF)
Supporting Information S1 Summary equations.
(DOCX)
Supporting Information S2 Model fitting and validation
with field data.
(DOCX)
Table 1. Main policy implications of modelling results.
Main policy implications:
1. High coverage with ACT treatment can produce a long-term reduction in malaria whereas the impact of MDA is generally only short-term
2. Primaquine enhances the effect of ACT in eliminating malaria and reduces the increase in proportion of artemisinin resistant infections
3. Parasite prevalence is a better surveillance measure for elimination programmes than numbers of symptomatic cases
4. Combinations of interventions are most effective
5. Sustained efforts are crucial for successful elimination.
doi:10.1371/journal.pone.0037166.t001
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Supporting Information S3 References for Supporting
Information.
(DOCX)
Table S1 Assumptions. The first 4 assumptions are likely to
decrease the efficacy of interventions, whereas the next 5
assumptions probably increase the efficacy, for the reasons given.
It is not known how the final assumption may affect the efficacy of
interventions.
(DOCX)
Table S2 Parameters. Where possible, these were taken
directly from the published field study data (‘Field study’) or by
fitting model output to results of the field study (‘Fitting’). Other
sources were unpublished interim reports for the field study
(‘Report’), unpublished surveillance data from the Cambodia
National Malaria Control Programme (CNM), discussion with the
staff who ran the field study at CNM or co-authors for this
manuscript (‘Verbal’). Parameters not specific to the field study
were based largely on expert opinion of the co-authors and were
derived from published data, where available, as stated below. For
those parameters for which a range of values is given, this reflects
uncertainty of their true value. For these parameters, the
underlined values were used to generate the plots and results
stated in the text and the ranges were used in the sensitivity
analyses. For the efficacy of drug resistance on pharmacodynam-
ics, as this is unknown, it was a modelled by multiplying the
clearance rate for each drug by its relative effectiveness against
resistant infections, e, such that 0#e#1.
(DOCX)
Table S3 Results of fitting the model to field data to
derive coverages of the different strategies employed in
the field study. One or both of prevalences of detected asexual
parasitaemia and gametocytes were fitted as indicated. Strategy A
was employed in 17 villages in Kampong Speu OD, B in 3 villages
in Kampot OD and C in 4 villages in Kampong Speu OD.
(DOCX)
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